ABT Maintained by Citigroup -- Price Target Raised to $112
ABT Maintained by Citigroup -- Price Target Raised to $112 GuruFocus
Covered in this story
What has happened since
- Abbott Laboratories is up 7.8% since this was published, 120 days ago.
- Citigroup is down 4.1% since this was published, 120 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Citi’s $112 target on $ABT is on the record and being tracked to Jul 2027 (12-month default), scored on the close that day.
Citi’s track record →Analyst targets on Abbott Laboratories
- Mizuho: at $103 · target $115 by Oct 2027 · Neutral via Investing.com
- StoneX: at $103 · target $120 by Oct 2027 · Buy via Investing.com
- BTIG: at $103 · target $125 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 34 stories mentioning Abbott Laboratories, the earliest published 6 May 2017.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.